ArticleJournal of cancer research and clinical oncology2017

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.

Marjut Niinivirta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.